Back

Patient Explorers

Trialist

Current states

BoNT-As are all largely the same. Choose based on the impact it can have on a patient’s experience. Use Dysport®, it is for more complex or severe spasticity

Desired states

See the positive impact that Dysport® can have on some of his patients. Encouraged and motivated to try Dysport® in additional patients

A. Demonstrate the impact of sustained goal-achievement for their patients
B. Provide reassurance in well-established safety profile
C. Convince HCPs on benefits of Dysport®

target

Messaging should be straight to the point, without complexity, with a focus on practical aspects of using Dysport®

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. Over 8 in 10 patients experience the early return of symptoms before their next injection*2
  2. 72% of patients who experience symptom recurrence (N=169) would like to have a treatment with effects that last longer2

Key supportive study :

  • Carenity study : Jacinto J. et al. Front Neurol 2020;11:388

Key material:

  • CLM presentation

Digital material for follow up:

  • Burden of disease (add link)

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. More patients can access treatment thanks to Dysport®’s broad reimbursement coverage in spasticity.
  2. Cost-effective treatment supports continuity of care and goal achievement without compromise.
  3. Broad reimbursement ensures timely initiation and sustained treatment, helping patients achieve functional goals and maintain independence

Key supportive reference:

RIZIV/INAMI :

Key material:

  • CLM presentation
  • Discover Dysport®

Digital material for follow up:

  • VAE reimbursement

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. Dysport® could provide sustained benefits in daily life, specifically in everyday tasks that involve carrying, reaching, grasping and releasing
  2. Dysport® helps enable patients to walk faster, giving them the confidence to maintain their independence
  3. Real-world studies (ULIS III, AboLiSh) confirm that these benefits are not just seen in trials, but are achieved in routine practice—cycle after cycle, with patient-chosen goals

Key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254, ULIS-III
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253, AboLiSh

Key material:

  • CLM presentation
  • AboLiSh infographic
  • ULIS-III infographic

Digital material for follow up:

  • GAS VAE
  • Goal seeting podcast Jacinto Ipsen Academy – Link
  • Goal seeting video Jacinto Ipsen Academy – Link

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. Dysport® helped reduce the early return of symptoms with 35% not needing reinjection until Week 16 or later*6
  2. Benefits were sustained in the second cycle, with 32% of patients not needing reinjection until Week 16 or later in the open-label extension (n=297)†7
  3. Dysport® demonstrated longer-lasting symptom control vs other BoNT-As in routine clinical practice in upper limb spasticity§16
  4. Reduced reinjection frequency (longer intervals) further minimizes overall treatment costs.

Main key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar (add link)
  • Jacinto reflection (add link)
  • VAE to Ipsen Academy
  • VAE on duration of response

Communication objective associated: Convince HCPs on benefits of Dysport®

Dysport® contains more active neurotoxin within the licensed maximum dose than any other available BoNT-A 62% of patients responded to Dysport® when the upper limb was their primary treatment target*†15 83% of patients responded to Dysport® when the lower limb was their primary treatment target*†15 Dysport® has a dose-response effect16 Recommended doses for upper / lower limb muscles10 The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered9

Main key supportive study :

  • Field M, et al. Toxins. 2018;10:535
  • Gracies J, et al. J Neurol Phys Ther. 2021;45:203-213. 

Key material:

  • CLM presentation
  • Dilution table
  • Reconstitution / Dosing leaflet
  • Muscle map

Digital material for follow up:

  • VAE reconstitution
  • VAE dosing
  • VAE Dysport in x points

Communication objective associated: Convince HCPs on benefits of Dysport®

  1. With 30 years of experience, Dysport® has a well-characterised safety profile at approved doses*10,11
  2. Dysport® offers a consistent safety profile across both low and high doses†‡§6,7

Main key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253

Key material:

  • CLM presentation

Communication objective associated: Provide reassurance in well-established safety profile

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early
return of debilitating symptoms3–7
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Main key supportive study :

  • Upper limb : Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb : Gracies J, et al. Neurology. 2017;89(22):2245-2253

Key material:

  • CLM presentation
  • Dosing app
  • Ixcellence website

Digital material for follow up:

  • Invitation to (inter)national training
  • Dosing app guide